Title |
Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
|
---|---|
Published in |
OncoTargets and therapy, April 2012
|
DOI | 10.2147/ott.s16289 |
Pubmed ID | |
Authors |
Putao Cen, Robert J Amato |
Abstract |
Pancreatic neuroendocrine tumors (PanNETs) are frequently diagnosed at unresectable stage and remain a medical challenge. Everolimus (RAD001, Afinitor(®), Novartis, Basel, Switzerland), an orally administered inhibitor of mammalian target of rapamycin (mTOR), was recently approved by the Food and Drug Administration to treat patients with advanced PanNETs. This review will examine the mechanism of action of everolimus, the function of mTOR and its inhibition, PanNETs and the mTOR pathway, and clinical trials of everolimus in PanNETs. Future investigations will focus on everolimus combination therapy to treat PanNETs and the discovery of predictive biomarkers for response to everolimus. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 3% |
Unknown | 29 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 27% |
Student > Master | 5 | 17% |
Student > Doctoral Student | 3 | 10% |
Student > Bachelor | 3 | 10% |
Researcher | 3 | 10% |
Other | 4 | 13% |
Unknown | 4 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 30% |
Agricultural and Biological Sciences | 7 | 23% |
Biochemistry, Genetics and Molecular Biology | 6 | 20% |
Nursing and Health Professions | 1 | 3% |
Social Sciences | 1 | 3% |
Other | 3 | 10% |
Unknown | 3 | 10% |